Get the Stockscreener App
0.6546
0.75%
0.0049
Aldeyra Therapeutics Inc stock is traded at $0.6546, with a volume of 505.54K.
It is up +0.75% in the last 24 hours and down -45.68% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$0.6497
Open:
$0.6569
24h Volume:
505.54K
Relative Volume:
0.42
Market Cap:
$39.49M
Revenue:
Net Income/Loss:
$-27.37M
P/E Ratio:
-1.438
EPS:
-0.4552
Net Cash Flow:
$-25.99M
1W Performance:
-1.58%
1M Performance:
-45.68%
6M Performance:
-57.77%
1Y Performance:
-87.51%
1-Day Range:
$0.6269
$0.665
1-Week Range:
$0.6035
$0.7499
52-Week Range:
$0.6035
$5.93
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
0.6546 | 39.49M | 0 | -27.37M | -25.99M | -0.4552 |
VRTX
Vertex Pharmaceuticals Inc
|
513.61 | 130.18B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.27 | 82.60B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
196.54 | 78.46B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
874.25 | 54.98B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.81 | 42.06B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Aldeyra Therapeutics, Inc. Estimates – NASDAQ:ALDX - TradingView
Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire
Aldeyra Therapeutics, Inc. (ALDX) Options Chain - Yahoo! Finance Canada
Aldeyra Therapeutics, Inc. (ALDX) Options Chain - Yahoo! Finance Canada
Why Is Aldeyra Therapeutics (NASDAQ:ALDX) Up 7.83% Pre-Market? The Catalyst, the Fundamentals and the Risks Before the Open - kalkine.ca
Which of Upstream Bio (NASDAQ:UPB), Biofrontera (NASDAQ:BFRI), Aldeyra Therapeutics (NASDAQ:ALDX), KALA BIO (NASDAQ:KALA) or Inovio Pharmaceuticals (NASDAQ:INO) Is the Best Biotech or Pharma Gainer in Pre-Market? - kalkine.ca
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research
Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Zacks Investment Research
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Zacks Investment Research
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research
Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye - Streetwise Reports
Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG - Moomoo
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect - ACCESS Newswire
H.C. Wainwright reiterates Neutral on Aldeyra stock at $2 target - Investing.com
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye DiseaseSlideshow (NASDAQ:ALDX) 2026-09-30 - Seeking Alpha
Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute ResolutionAldeyra Therapeutics (NASDAQ:AL - Benzinga
ALDX Reiterated by BTIG -- Price Target Maintained at $9.00 - GuruFocus
Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease - ophthalmologytimes.com
BTIG reiterates Buy rating on Aldeyra Therapeutics, $9 price target - TradingView
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease - Yahoo Finance
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter - Yahoo Finance
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Aldeyra to appeal FDA rejection of dry eye drug reproxalap - Investing.com
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com - Investing.com India
Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease - tradingview.com
After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug. - Stock Titan
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease - Yahoo Finance
Aldeyra Therapeutics to Host Regulatory Update Webcast - FinancialContent
Aldeyra Therapeutics to Host Regulatory Update Webcast - Yahoo Finance
Aldeyra Therapeutics Inc (ALDX) Stock Price Target & Forecast - TradingKey
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ALDX: Aldeyra Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Zacks Investment Research
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? - Zacks Investment Research
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-09-06 | Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALDX | Press Release - stockhouse.com
Aldeyra Therapeutics, Inc. (ALDX) Options Chain - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out - ACCESS Newswire
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DOUGLAS RICHARD | Director |
Mar 19 '26 |
Buy |
1.40 |
70,000 |
98,000 |
195,000 |
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
2.18%
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):